EMA confirms suspension of sickle cell disease medicine - Oxbryta

According to the European's Medicines Agency's  Committee for Medicinal Products for Human Use (CHMP), a higher rate of death and disease complications in recent trials means benefit-risk balance no longer favourable. The CHMP opinion will now be forwarded to the European Commission, which will issue a final legally binding decision applicable in all EU Member States.

Read the full publication here: https://www.ema.europa.eu/en/news/ema-confirms-suspension-sickle-cell-disease-medicine-oxbryta